Fig. 3

FAK inhibition by TKI defactinib hampers tumor properties of PDAC cells. a. Treatment with defactinib reduced PDAC cell proliferation (averages with corresponding SEM are visualized). b. Western blot analysis after 2 h of exposure to 10 μM defactinib showed reduced phosphorylation of activation site pY-397 and pY-925, but not pY-576/577. c. Heatmap of FAK p-site log intensities after defactinib drug perturbation showed downregulation of multiple p-sites of FAK including regulatory site pY-397 (red = upregulated, green = downregulated, black = not detected). d. Migration at 24 h assessed by scratch assays was significantly hampered by treatment with 1 μM defactinib in Suit-2 and primary cell line PDAC1 (Error bars depict SEM of at least 3 biological replicates)